CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Clinical implication of adjuvant chemotherapy according to mismatch repair status in patients with intermediate-risk stage II colon cancer
Byung Woog Kang, Dong Won Baek, Eunhye Chang, Hye Jin Kim, Su Yeon Park, Jun Seok Park, Gyu Seog Choi, Jin Ho Baek, Jong Gwang Kim

DOI: https://doi.org/10.12701/yujm.2021.01571

Excel Download

Views of Australian Medical Oncologists Regarding the Use of Mismatch Repair Status to Assist Adjuvant Chemotherapy Recommendations for Patients With Early-Stage Colon Cancer
Clinical Colorectal Cancer. 2015;14(3):192-197   Crossref logo
Link1 Link2

ERCC1, Defective Mismatch Repair Status as Predictive Biomarker of Survival for Stage III Colon Cancer Patients Receiving Oxaliplatin Based Adjuvant Chemotherapy
Annals of Oncology. 2012;23:ix180   Crossref logo
Link1 Link2

ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
British Journal of Cancer. 2013;108(6):1238-1244   Crossref logo
Link1 Link2 Link3

Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer
International Journal of Cancer. 2016;139(1):187-193   Crossref logo
Link1 Link2

Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer
Cancer. 2014;121(4):527-534   Crossref logo
Link1 Link2

Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer
Cancer. 2016;122(21):3277-3287   Crossref logo
Link1 Link2

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
Frontiers in Oncology. 2020;10:   Crossref logo
Link1

A Combined Analysis of Mismatch Repair Status and Thymidylate Synthase Expression in Stage II and III Colon Cancer
Clinical Colorectal Cancer. 2013;12(2):128-135   Crossref logo
Link1 Link2

Should adjuvant chemotherapy be recommended to a 75-year-old woman with deficient mismatch repair (dMMR) gene product expression seen in a stage II colon adenocarcinoma with lymphovascular invasion?
Current Problems in Cancer. 2018;42(6):601-604   Crossref logo
Link1 Link2

Eligibility of Real-World Patients With Stage II and III Colon Cancer for Adjuvant Chemotherapy Trials
Clinical Colorectal Cancer. 2020;19(4):e226-e234   Crossref logo
Link1 Link2